New combo for advanced solid tumors after standard therapy
Part of Cancer clinical trials.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced lung cancer (NSCLC) that has spread and can't be removed with surgery or radiation, or you have another solid tumor that hasn't responded to standard treatments.
- You do not have a known genetic change (like EGFR or ALK) for which approved pills are available.
- You have already tried a PD-1/PD-L1 drug (like pembrolizumab) plus platinum chemotherapy, and it stopped working.
- You have at least one tumor that can be measured on a scan, and you are in good enough health to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two investigational drugs (SCTB41 and SCTB39G), sometimes given with standard treatment, for advanced solid tumors. The goal is to see if this approach can shrink tumors and control the cancer, and it may be an option for people who have exhausted standard treatments.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests two new study drugs (SCTB41 and SCTB39-1) given together, sometimes with standard treatment, to see if they are safe and effective against advanced solid tumors. If you join, you will receive these drugs and be monitored for how well they fight the cancer.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.